All-oral treatment with daclatasvir and asunaprevir for HCV genotype 1 and impact of add-on therapy with lipid modulators

Kohjima M
Motomura K
Koyanagi T
Tada S
Yamashita N
Sato T
Nagase S
Sugimoto R
Yokota M
Uchimura K
Sakai H
Higashi N
Morizono S
Kuniyoshi M
Tokumatsu M
Honda M
Yoshimoto T
Higuchi N
Fukuizumi K
Kotoh K
Ohe K
Enjoji M
Kato M
Nakamuta M

Adv Res Gastroenterol Hepatol